Pro Numb Tattoo Numbing Spray, LLC - 722589 - 04/14/2026

Why It Matters

Non‑compliance jeopardizes consumer safety and can trigger costly recalls, while signaling heightened regulatory scrutiny for the fast‑growing OTC drug market.

Key Takeaways

• FDA issued warning for unapproved OTC numbing sprays
• Company failed batch release testing and raw material verification
• Products labeled as new drugs violate sections 505(a) and 301(d)
• Lack of stability data and process validation endangers consumer safety
• FDA demands CAPA plan, lab qualifications, and product recalls

Pulse Analysis

The Food and Drug Administration’s recent warning to Pro Numb Tattoo Numbing Spray underscores the agency’s relentless focus on enforcing CGMP standards across the over‑the‑counter (OTC) drug sector. By flagging failures in batch release testing, raw‑material verification, and stability studies, the FDA is sending a clear message that even niche manufacturers must adhere to the same rigorous quality‑control protocols as larger pharmaceutical firms. Non‑compliant products are deemed adulterated and misbranded, exposing companies to enforcement actions, import bans, and significant reputational damage.

For Pro Numb, the violations are especially consequential because the company marketed its lidocaine‑based sprays as new drugs without FDA approval, breaching sections 505(a) and 301(d) of the FD&C Act. The lack of documented testing for identity, strength, purity, and microbial limits raises the risk of sub‑potent or contaminated products reaching consumers, potentially causing adverse skin reactions or ineffective pain relief. Moreover, the absence of a validated stability program means expiration dates cannot be scientifically supported, further eroding consumer trust and inviting liability.

Looking ahead, the firm must develop a comprehensive corrective‑and‑preventive action (CAPA) plan that includes independent laboratory assessments, robust supplier qualification, and full retrospective testing of retained batches. This case serves as a cautionary tale for other OTC manufacturers: investing in validated processes, thorough documentation, and proactive regulatory engagement is not optional but essential for market sustainability. Companies that prioritize compliance can avoid costly recalls, maintain FDA goodwill, and protect both public health and their bottom line.